insulin glargine   Click here for help

GtoPdb Ligand ID: 7572

Synonyms: HOE-901 | HOE901 | Lantus®
Approved drug
insulin glargine is an approved drug (FDA and EMA (2000))
Comment: Insulin glargine is a recombinant, modified analogue of human insulin. A fixed-ratio formulation containing insulin glargine and lixisenatide is being assessed in clinical trials for the treatment of type 2 diabetes. Click here to view a list of such trials registered with

Biosimilar drugs: Insulin glargine biosimilar SB9 is in development by Samsung Bioepis
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: glargine

No information available.
Summary of Clinical Use Click here for help
Used to treat diabetes types 1 and 2.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
The amino acid modifications in insulin glargine do not alter the pharmocological effect of the insulin, but alter the drug's pharmacokinetics/pharmacodynamics. Insulin glargine crystalises at physiological pH when injected subcutaneously. These crystals dissolve slowly and provide a more regular and longer-lasting release of insulin into the bloodstream compared to natural insulin.
External links Click here for help